

SIGA Adds Vice President of Clinical and Regulatory Affairs to Management Team

NEW YORK, May 07, 2008 (BUSINESS WIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced the appointment of Seane Jones as the new Vice President of Clinical and Regulatory Affairs, effective April 29, 2008. Ms. Jones will direct the execution of the company's ongoing regulatory strategy and will have responsibility for all regulatory submissions with respect to SIGA's product candidates.

Ms. Jones is an accomplished regulatory affairs professional with experience bringing drug candidates through the regulatory process in the United States and internationally, including in the European Union. Prior to joining SIGA, Ms. Jones was with Alcon Laboratories, where she served as Director of Regulatory Affairs, ENT and Generics. While at Alcon Laboratories, Inc., she managed the FDA filing of 8 Investigational New Drug Applications and 5 New Drug Applications, 4 of which went on to receive NDA approval. Prior to this, she held roles at Geneva Pharmaceuticals, Inc., Steris Laboratories and Pathogenesis Corp.

Dr. Eric A. Rose, SIGA's Chief Executive Officer, commented, "We are delighted to have Seane as a member of SIGA's management team and bring to bear her considerable experience in the development and approval processes associated with small molecule compounds. Her successful track record seeing drugs through the regulatory approval process, both in the U.S. and abroad, makes her a valuable asset as we enter the final stages in the approval of ST-246, our small molecule orthopoxvirus inhibitor intended for the treatment of smallpox and other orthopoxvirus diseases. Seane's knowledge and insight will also help pave the way for several of our other programs that are at an earlier stage in the development pipeline."

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's Web site at <http://www.siga.com/>.

Forward-looking Statements

This press release contains or implies certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the continued development and possible eventual approval of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond SIGA's control. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce sufficient legal rights in its products, including sufficient patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at <http://www.sec.gov>. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

SOURCE: SIGA Technologies, Inc.

Tfromer@kcsa.com

or

Marybeth Csaby, 212-896-1236

mcsaby@kcsa.com

or

David Burke, 212-896-1258

dburke@kcsa.com

Copyright Business Wire 2008

News Provided by COMTEX